Silicon opens laboratory facilities in San Diego
The combined offices and laboratories will allow the company to leverage the capabilities of the DEPArray system in the recovery of single pure cells by offering a rare
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.
The harmful active pharmaceutical ingredients include diclofenac sodium and methocarbamol. Reumofan Plus, labeled in Spanish, is used for treating arthritis, muscle pain, osteoporosis, bone cancer, and other conditions.